You are here

  • Home
  • Archive
  • Volume 29, Issue 9
  • Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety

Article metrics

Article menu

Download PDFPDF

Original article
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety

 

Online download statistics by month:

Online download statistics by month: November 2019 to April 2024

AbstractFullPdf
Nov 2019364357114
Dec 201928728663
Jan 202014314233
Feb 2020918640
Mar 2020868335
Apr 2020928337
May 2020858452
Jun 2020424126
Jul 2020807932
Aug 2020656423
Sep 2020535344
Oct 2020636132
Nov 2020434024
Dec 2020585520
Jan 2021646324
Feb 2021373431
Mar 2021343436
Apr 2021625547
May 2021494830
Jun 2021454227
Jul 2021282727
Aug 2021514929
Sep 2021363425
Oct 2021727138
Nov 2021414024
Dec 2021414126
Jan 2022585825
Feb 2022374024
Mar 2022393644
Apr 2022747417
May 2022767634
Jun 2022565318
Jul 2022596018
Aug 2022525115
Sep 2022545620
Oct 2022524723
Nov 2022312814
Dec 2022313013
Jan 2023403819
Feb 2023828014
Mar 202340407
Apr 202324245
May 2023292813
Jun 2023312713
Jul 2023161718
Aug 202326269
Sep 2023181711
Oct 2023292815
Nov 202320199
Dec 2023272517
Jan 20242098
Feb 2024241715
Mar 2024191915
Apr 202418186
Total319430931398